N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations

Nicolas Sluis-Cremer, Katie Moore, Jessica Radzio, Secondo Sonza, Gilda Tachedjian

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
Original languageEnglish
Pages (from-to)317 - 319
Number of pages3
JournalAIDS
Volume24
Issue number2
DOIs
Publication statusPublished - 2010

Cite this

@article{4297e95dbfc749da984fe6f189598ab2,
title = "N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations",
abstract = "We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.",
author = "Nicolas Sluis-Cremer and Katie Moore and Jessica Radzio and Secondo Sonza and Gilda Tachedjian",
year = "2010",
doi = "10.1097/QAD.0b013e3283315697",
language = "English",
volume = "24",
pages = "317 -- 319",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. / Sluis-Cremer, Nicolas; Moore, Katie; Radzio, Jessica; Sonza, Secondo; Tachedjian, Gilda.

In: AIDS, Vol. 24, No. 2, 2010, p. 317 - 319.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations

AU - Sluis-Cremer, Nicolas

AU - Moore, Katie

AU - Radzio, Jessica

AU - Sonza, Secondo

AU - Tachedjian, Gilda

PY - 2010

Y1 - 2010

N2 - We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.

AB - We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.

UR - http://www.ncbi.nlm.nih.gov/pubmed/20010074

U2 - 10.1097/QAD.0b013e3283315697

DO - 10.1097/QAD.0b013e3283315697

M3 - Article

VL - 24

SP - 317

EP - 319

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -